Indiana University study finds cardiovascular drug may offer new treatment for some difficult types of leukemia:

A drug now prescribed for cardiovascular problems could become a new tool in physicians’ arsenals to attack certain types of leukemia that so far have evaded effective treatments, Indiana University researchers say. The drug, Fasudil, has been used to treat stroke patients because it is a vasodilator, meaning it dilates blood vessels. However, its potential in leukemia emerged because its method of action is blocking the activity of a protein called Rho kinase, or ROCK.

Click here to read the full press release from Indiana University

Among the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.